Suppr超能文献

硫唑嘌呤:分子作用与临床作用

Tiazofurin: molecular and clinical action.

作者信息

Weber G, Prajda N, Abonyi M, Look K Y, Tricot G

机构信息

Laboratory for Experimental Oncology, Indiana University School of Medicine, Indianapolis 46202, USA.

出版信息

Anticancer Res. 1996 Nov-Dec;16(6A):3313-22.

PMID:9042306
Abstract

UNLABELLED

The purpose is to provide an overview of the molecular and clinical impact of tiazofurin.

METHOD

The biochemical and clinical techniques were reported (1, 2).

RESULTS

IMP DH activity increased in various animal and human tumors and was particularly high in leukemic blast cells. The increased activity was due to an elevation in the mRNA concentration of type II isozyme. Tiazofurin, a C-nucleoside, was converted in sensitive cells to the active metabolite, TAD, which tightly bound at the NADH site inhibited IMP DH activity. The inhibition led to decreased GTP concentration, down-regulation of ras and myc oncogenes and induced maturation of blast cells. New evidence shows that tiazofurin injection downregulated signal transduction activity due to a reduction of the activities of PI and PIP kinases leading to a decrease in the concentration of the second messenger, IP3. In patients; tiazofurin infusion and allopurinol administration led to reduction of IMP DH activity and GTP concentration. Allopurinol inhibited xanthine oxidase activity leading to a marked rise in hypoxanthine concentration which inhibited the increased guanine salvage pathway. In the clinic, the increase in serum hypoxanthine concentration is essential for the success of tiazofurin treatment. Tiazofurin showed additivity or synergism with ribavirin, retinoic acid, taxol, quercetin, gemcitabin, dipyridamole and brefeldin. Ribavirin which inhibits IMP DH at the IMP site has been shown to prolong the IMP depressing action of tiazofurin in rat bone marrow cells.

CONCLUSION

Tiazofurin and allopurinol achieve reduction of GTP concentration in leukemic blast cells through inhibition of IMP DH and GPRT activities. As a result, induced maturation occurs with down-regulation of ras and myc oncogenes and probably reduced signal transduction capacity. Tiazofurin in leukemic patients provides over 75% therapeutic responses and patients can be treated with this combination for many months with good quality of life. These clinical and biochemical results were recently confirmed independently (3).

摘要

未标记

目的是概述替唑呋林的分子和临床影响。

方法

报告了生化和临床技术(1,2)。

结果

IMP脱氢酶活性在各种动物和人类肿瘤中增加,在白血病原始细胞中尤其高。活性增加是由于II型同工酶的mRNA浓度升高。替唑呋林,一种C核苷,在敏感细胞中转化为活性代谢物TAD,其在NADH位点紧密结合抑制IMP脱氢酶活性。这种抑制导致GTP浓度降低,ras和myc癌基因下调,并诱导原始细胞成熟。新证据表明,替唑呋林注射由于PI和PIP激酶活性降低导致信号转导活性下调,从而导致第二信使IP3浓度降低。在患者中,替唑呋林输注和别嘌呤醇给药导致IMP脱氢酶活性和GTP浓度降低。别嘌呤醇抑制黄嘌呤氧化酶活性导致次黄嘌呤浓度显著升高,从而抑制鸟嘌呤补救途径的增加。在临床上,血清次黄嘌呤浓度的升高对于替唑呋林治疗的成功至关重要。替唑呋林与利巴韦林、视黄酸、紫杉醇、槲皮素、吉西他滨、双嘧达莫和布雷菲德菌素表现出相加或协同作用。已证明在IMP位点抑制IMP脱氢酶的利巴韦林可延长替唑呋林在大鼠骨髓细胞中的IMP抑制作用。

结论

替唑呋林和别嘌呤醇通过抑制IMP脱氢酶和GPRT活性降低白血病原始细胞中的GTP浓度。结果,诱导成熟发生,ras和myc癌基因下调,信号转导能力可能降低。白血病患者使用替唑呋林的治疗反应率超过75%,患者可以用这种联合治疗数月,生活质量良好。这些临床和生化结果最近得到了独立证实(3)。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验